A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fruquintinib in Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 27 Jul 2018
At a glance
- Drugs Fruquintinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Hutchison MediPharma
- 27 Jul 2018 According to Chi-Med media release, the company intended to complete this study at the end of 2018.
- 15 Dec 2017 According to a Chi Med media release, the first drug dose was administered earlier this month.
- 16 Nov 2017 Status changed from not yet recruiting to recruiting.